News | February 25, 2025
Biocon Biologics launches Yesintek Biosimilar to Stelara in US
YESINTEK is approved for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis
YESINTEK is approved for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis
Findings to form the basis for a Phase 3 program, anticipated to start in H2 2025
Amgen India investment totals $200 million through 2025
This innovative platform is strategically essential to developing and scaling high-value life sciences use cases such as streamlining the content supply chain
Cipla Limited has received final approval from the USFDA for the New Drug Application submitted for ‘Nilotinib Capsules 50, 150 and 200 mg’
The acquisition aligns with Granules' vision to enter the rapidly expanding peptide-based anti-diabetic and anti-obesity market
Aster commits to increase bed capacity in the State via capacity expansion and greenfield projects
Ibuprofen and famotidine combination is indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis
Collaborates with VisionSpring to conduct eye check-up camps for underprivileged children
Subscribe To Our Newsletter & Stay Updated
_256_384.JPG)
